Drug discovery

#Cancer research #Drug development #Drug discovery #Oncology #Screening

Learn about the rapid bioenergetic functional screening of anticancer drug candidates

The regulation of cellular bioenergetics is recognised as a key driver of cancer cell proliferation. Identifying key pathways that modulate bioenergetic metabolism is a promising strategy for developing novel therapeutics for cancer treatment. In this App Note you will learn: How the Agilent Seahorse XF Real Time ATP rate assay… Read More

#Resources

#AI #Drug discovery #Generative AI #Machine learning #Webinar

Generative AI webinar: Turning drug discovery into a technological pursuit

This webinar supported by Thermo Fisher Scientific and presented by Generate:Biomedicines will be free to attend on 12 October 9am EDT / 2pm BST / 3pm CEST. The webinar, hosted by DDW, will feature the expertise of Adam Root, Vice President, Protein Sciences at Generate:Biomedicines who will discuss how an… Read More

#News

#App note #Assays #Drug development #Drug discovery #Kinetics #Sartorius

Download now: Optimise kinetic assays to avoid avidity effects

‘Optimising kinetic assays to avoid avidity effects’ – a new free resource – is now available from Sartorius and DDW. What you will learn: Researchers from ChromoTek discuss the differences between affinity and avidity as measured on the Octet BLI platform Measuring affinity in avidity driven assay orientations Why assay… Read More

#News

#AI / data analytics / healthtech / informatics #Biotechnology #Drug development #Drug discovery #Technology

This week in drug discovery (11-15 September)  

News round-up for 11-15 September by DDW Digital Content Editor Diana Spencer. Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development. Read More

#News

#Assays #Drug development #Drug discovery #Kinetics

Optimising kinetic assays to avoid avidity effects

What you will learn: Researchers from ChromoTek discuss the differences between affinity and avidity as measured on the Octet® BLI platform Measuring affinity in avidity driven assay orientations Why assay orientation, valency, ligand surface density and non-specific binding matter Recognise and resolve issues arising from interactions that contain a bivalent… Read More

#Resources

microRNA
#App note #Drug development #Drug discovery #mRNA #Purification technology #Screening

App Note: Achieve mRNA binding with DBC values over 6mg/mL

A new Application Note is now available to download from Sartorius BIA Separations. In this App Note, multi-parallel screening of binding conditions on CIM Oligo dT 96-well plates was performed to optimise the dynamic binding capacity (DBC) in the shortest time possible. What you will learn: How to effectively use Monolithic 96-well plates… Read More

#News

#Drug development #Drug discovery #mRNA #Purification technology #Screening

Discover how to achieve mRNA binding on Oligo dT with DBC values over 6mg/mL

In this Application Note, multi-parallel screening of binding conditions on CIM® Oligo dT 96-well plates was performed to optimise the dynamic binding capacity (DBC) in the shortest time possible. What you will learn: How to effectively use Monolithic 96-well plates when developing methods. They are unique on the market in combining the… Read More

#Resources

Cancer cells
#biological engineering #Bolt Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Immunology

New podcast: In conversation with Shelley Ackerman, Bolt Biotherapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Shelley… Read More

#News

Automation concept
#Automation #Drug discovery #Lab automation #Laboratory

Busting common myths about lab automation 

Ernesto Staroswiecki, Senior Manager, R&D, at Beckman Coulter Life Sciences takes readers through common lab automation myths.  Many clinical and research laboratories today are having to do more with less: faced with ongoing staffing shortages, increased workloads, and budgetary constraints, many laboratory managers are feeling the stress, which… Read More

#Exclusive Content

Quantum drug discovery
#Artificial intelligence (AI) #Drug design #Drug discovery #Enzymes #Funding #Kuano #Quantum computing

£1.8 million raised to accelerate quantum drug discovery 

Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, has raised £1.8M in seed funding, which will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes, as well as continued company growth… Read More

#Business & Investment #News

Future lab, AI and digital data
#Artificial intelligence (AI) #Benchling #Drug discovery #Lab automation #Proscia #Webinar

Webinar: Key benefits and latest innovations in AI and lab automation

Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More

#News

#Collaboration #Drug development #Drug discovery #Horizon Europe #Mergers and acquisitions #Partnership

New: DDW Highlights 11 September 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen the vital importance of collaboration to the… Read More

#News

AI brain
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Pharmaceutical industry

Pharma must embrace an AI future says new report

Artificial intelligence (AI) technology has the potential to revolutionise drug discovery and pharma companies need to make plans for a future in which AI is frequently utilised in research, says ResearchAndMarkets.com. However, the change AI will bring about in drug discovery will take some time, according… Read More

#News #Trends & Analysis

#Collaboration #Drug development #Drug discovery #Horizon Europe #Mergers and acquisitions #Partnership

This week in drug discovery (4-8 September)  

News round-up for 4-8 September by DDW Digital Content Editor Diana Spencer. This week we have seen the vital importance of collaboration to the successful development and discovery of novel therapeutics, exemplified by the new deal agreed by the UK and EU to admit the UK… Read More

#News

#Cell and protein analysis #Drug development #Drug discovery #Mass spectrometry / NMR #Regulatory

Podcast: Mass spectrometry advancing drug discovery

This is the latest episode of the free DDW narrated podcast, “How is mass spectrometry advancing drug discovery?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Native mass spectrometry: Drug discovery’s new kid on the… Read More

#News

Business financing
#Apollo Therapeutics #Drug discovery #Funding

Apollo Therapeutics closes $226.5 million Series C financing 

Apollo Therapeutics, a biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, has closed $226.5 million in a Series C financing, led by lead investor Patient Square Capital.  Financing significantly adds to the $195 million previously raised by the company, and to… Read More

#Business & Investment #News